Switch theme
Sign up to access all valuation multiples
Anhui Huaren Health Pharmaceutical Co Ltd focuses on the pharmaceutical retail industry and forms a retail chain, retail centralized procurement, retail service, and retail e-commerce system.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anhui Huaren Health has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Anhui Huaren Health achieved revenue of $523M and an EBITDA of $51.3M.
Anhui Huaren Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anhui Huaren Health valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $449M | $523M | XXX | XXX | XXX |
| Gross Profit | $112M | $146M | XXX | XXX | XXX |
| Gross Margin | 25% | 28% | XXX | XXX | XXX |
| EBITDA | $53.2M | $51.3M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 10% | XXX | XXX | XXX |
| Net Profit | $9.6M | $22.2M | XXX | XXX | XXX |
| Net Margin | 2% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Anhui Huaren Health's stock price is CNY 11 (or $2).
Anhui Huaren Health has current market cap of CNY 4.5B (or $615M), and EV of CNY 4.6B (or $631M).
See Anhui Huaren Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $631M | $615M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Anhui Huaren Health has market cap of $615M and EV of $631M.
Anhui Huaren Health's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Anhui Huaren Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Anhui Huaren Health and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $631M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 12.3x | XXX | XXX | XXX |
| P/E | 38.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -53.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAnhui Huaren Health's NTM/LTM revenue growth is n/a
Anhui Huaren Health's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $23K for the same period.
Over next 12 months, Anhui Huaren Health's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Anhui Huaren Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Anhui Huaren Health and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $23K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 26% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anhui Huaren Health acquired XXX companies to date.
Last acquisition by Anhui Huaren Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Anhui Huaren Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Anhui Huaren Health founded? | Anhui Huaren Health was founded in 2001. |
| Where is Anhui Huaren Health headquartered? | Anhui Huaren Health is headquartered in China. |
| How many employees does Anhui Huaren Health have? | As of today, Anhui Huaren Health has 6K+ employees. |
| Is Anhui Huaren Health publicy listed? | Yes, Anhui Huaren Health is a public company listed on SHE. |
| What is the stock symbol of Anhui Huaren Health? | Anhui Huaren Health trades under 301408 ticker. |
| When did Anhui Huaren Health go public? | Anhui Huaren Health went public in 2023. |
| Who are competitors of Anhui Huaren Health? | Similar companies to Anhui Huaren Health include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Anhui Huaren Health? | Anhui Huaren Health's current market cap is $615M |
| What is the current revenue growth of Anhui Huaren Health? | Anhui Huaren Health revenue growth between 2023 and 2024 was 16%. |
| Is Anhui Huaren Health profitable? | Yes, Anhui Huaren Health is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
